Welcome to IJSDR UGC CARE norms ugc approved journal norms IJRTI Research Journal | ISSN : 2455-2631
International Peer Reviewed & Refereed Journals, Open Access Journal
ISSN Approved Journal No: 2455-2631 | Impact factor: 8.15 | ESTD Year: 2016
Scholarly open access journals, Peer-reviewed, and Refereed Journals, Impact factor 8.15 (Calculate by google scholar and Semantic Scholar | AI-Powered Research Tool) , Multidisciplinary, Monthly, Indexing in all major database & Metadata, Citation Generator, Digital Object Identifier(DOI)

Issue: March 2023

Volume 8 | Issue 3

Impact factor: 8.15

Click Here For more Info

Imp Links for Author
Imp Links for Reviewer
Research Area
Subscribe IJSDR
Visitor Counter

Copyright Infringement Claims
Indexing Partner
Published Paper Details
Paper Title: Comparison of efficacy and safety of single and combinational therapy of sglt-2in in treatment of diabetes mellitus
Authors Name: Dhanush Bellapu , Ramya Sravanthi , Tahera Mubeen , Padmalatha Kantamaneni , Ronald Darwin
Unique Id: IJSDR2303042
Published In: Volume 8 Issue 3, March-2023
Abstract: Abstract Diabetes mellitus is a chronic condition which requires firm glycaemic control with the help of medications and life style changes. Sodium glucose co-transporter 2 inhibitors are novel drugs which exhibit immense benefits on diabetic patients. Currently FDA approved three SGLT-2 where the mode of action is directed towards kidney in potentiating glucose excretion and has pleiotropic effects on reducing HbA1c levels, patient body weight, lipid profile to some extent and blood pressure. Their major positive effects are believed to be focused on cardiovascular and renal functions. SGLT-2 inhibitors especially Dapagliflozin was indicated not only in the management of type 2 diabetes mellitus but also approved for type 1 diabetes mellitus thus providing a way to reduce insulin dose. Risk of hypoglycaemia is significantly increased with use of SGLT-2 inhibitors and insulin in type 1 diabetics but there is no risk when used alone. Many clinical trials were performed and few ongoing trials also suggested good efficacy and safety profiles with use of SGLT-2 inhibitors. Although the use of SGLT-2 inhibitors alone known to be efficacious, their use with other anti-diabetic drug classes presented promising effects. However, SGLT-2 inhibitors are also associated with adverse events such as urinary and genital tract infections, diabetic ketoacidosis, fractures, amputation and kidney injury thus requiring special attention to minimise such effects with appropriate diagnosis and management for better patient survival outcomes. Appropriate SGLT-2 inhibitor use with close patient monitoring, considering prior preventive measures and medication adherence are factors that improve quality of life.
Keywords: Keywords: diabetes mellitus, SGLT-2in, hypoglycaemia, adverse events.
Cite Article: "Comparison of efficacy and safety of single and combinational therapy of sglt-2in in treatment of diabetes mellitus", International Journal of Science & Engineering Development Research (www.ijsdr.org), ISSN:2455-2631, Vol.8, Issue 3, page no.259 - 262, March-2023, Available :http://www.ijsdr.org/papers/IJSDR2303042.pdf
Downloads: 00032
Publication Details: Published Paper ID: IJSDR2303042
Registration ID:204372
Published In: Volume 8 Issue 3, March-2023
DOI (Digital Object Identifier):
Page No: 259 - 262
Publisher: IJSDR | www.ijsdr.org
ISSN Number: 2455-2631

Click Here to Download This Article

Article Preview

Click here for Article Preview

Major Indexing from www.ijsdr.org
Google Scholar ResearcherID Thomson Reuters Mendeley : reference manager Academia.edu
arXiv.org : cornell university library Research Gate CiteSeerX DOAJ : Directory of Open Access Journals
DRJI Index Copernicus International Scribd DocStoc

Track Paper
Important Links
Conference Proposal
DOI (A digital object identifier)

Providing A digital object identifier by DOI
How to GET DOI and Hard Copy Related
Open Access License Policy
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
Creative Commons License
This material is Open Knowledge
This material is Open Data
This material is Open Content
Social Media

Indexing Partner